International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 35-37 , April 2009

Medical treatment of insulinomas: The role of diphenylhydantoin

References 

  1. Harris S. Hyperinsulinism and dysinsulinism. JAMA. 1924;83:729
  2. Wider RM, Allan FN, Power MH. Carcinoma of the islands of the pancreas. JAMA. 1927;89:348
  3. Howland G, Campbell WR, Malthby EJ. Dysinsulinism, convulsion and coma due to islet cell tumor of the pancreas, with operation and cure. JAMA. 1992;93:674–679
  4. Sanbar SS, Conway FJ, Zweifler AJ, et al. Diabetogenic effect of dilantin (abs.). Diabetes. 1967;16:533
  5. Klein JP. Diphenylhydantoin intoxication associated with hyperglycemia. J Pediat. 1966;69(3):463–465
  6. Dahl JR. Diphenylhydantoin toxic psychosis with associated hyperglycemia. Calif Med. 1967;107(4):345–347
  7. Said DM, Fraga JR, Reichelderfer TE. Hyperglycemia associated with diphenylhydantoine (dilantin) intoxication. Med Ann Dist Columbia. 1968;37(3):170–172
  8. Goldberg EM, Sanbar SS. Hyperglycemic, nonketotic coma following administration of dilantin (diphenylhydantoin). Diabetes. 1969;18(2):101–106
  9. Peters BH, Samaan NA. Hyperglycemia with relative hypoinsulinemia in diphenylhydantoin toxicity. New Eng J Med. 1969;281(2):91–92
  10. Levin SR, Booker J, Smith DF, et al. Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas. J Clin Endocrinol Metab. 1970;30(3):400–401
  11. Malherbe C, Burrill KC, Levin SR, et al. Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med. 1972;286:339–341
  12. Draznin B, Ayalon D, Hoerer E, et al. Effect of diphenylhydantoin on patterns of insulin secretion in obese subjects. Acta Diabetol Lat. 1977;14:51–61
  13. Hofeldt FD, Dippe SE, Levin SR, et al. Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes. 1974;23:192–198
  14. Perry-Keene DA, Larkins RG, Heyma P, et al. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a randomized trial. Clin Endocrinol (Oxf). 1980;12:575–580
  15. Festoff BW, Appel SH. Effect of diphenylhydantoin on synaptosome sodium–potassium-ATPase. J Clin Invest. 1968;47(12):2752–2758
  16. Kizer JS, Vargas-Cordon M, Brendel K, et al. The in vitro inhibition of insulin secretion by diphenylhydantoin. J Clin Invest. 1970;49:1942–1948
  17. Levin SR, Kasson BG, Driessen JF. Adenosin triphosphateses of rat pancreatic islets: comparison of those with rat kidney. J Clin Invest. 1978;62:692–701
  18. Hales CN, Milner RDG. The role of sodium and potassium in insulin secretion from rabbit pancreas. J Physiol (Lond). 1968;194:725–743
  19. Grodsky GM, Bennett LL. Cation requirements for insulin secretion in the isolated perfused pancreas. Diabetes. 1966;15:910–913
  20. Lebrun P, Sener A, Malaisse WJ, et al. Diphenylhydantoin inhibits calcium fluxes and insulin release in pancreatic islets. Ann Endocrinol (Paris). 1981;42(3):291–292
  21. Nabe K, Fujimoto S, Shimodahira M, et al. Diphenylhydantoin supresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Endocrinology. 2006;147:2717–2727
  22. Gerich J, Charles MA, Levin SR, et al. In vitro inhibition of pancreatic glucagon secretion by diphenylhydantoin. J Clin Endocrinol Metab. 1972;35:823
  23. Machina T, Marcus R, Levin SR. Inhibition of glucagon secretion by diphenylhydantoin in a patient with glucagonoma. West J Med. 1980;132:357
  24. Cohen MS, Bower RH, Fidler SM, et al. Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet. 1973;301(7793):40–41
  25. Pelkonen R, Taskinen MR. Effect of diphenylhydantoin on plasma insulin in insulinoma. Lancet. 1973;1:604–605
  26. Arnaout MA, Salti I. Phenytoin in benign insulinoma. Lancet. 1976;1:861
  27. Imanaka S, Matsuda S, Ito K, et al. Medical treatment for inoperable insulinoma: clinical usefulness of diphenylhydantoin and diltiazem. Jpn J Clin Oncol. 1986;16:65–71
  28. Levin SR, Grodsky GM, Hagura R, et al. Comparison of the inhibitory effects of diphenylhydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas. Diabetes. 1972;21:856–862
  29. Curry DL, Bennett LL, Grodsky GM. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology. 1968;83:572–584
  30. Grodsky GM, Curry D, Landahl H, et al. Further studies on the dynamic aspects of insulin release in vitro with evidence for a two-compartmental storage system. Acta Diabetol Lat. 1969;6(Suppl. 1):554–578
  31. Kizer JS, Vargas-Cordon M, Brendel K, et al. The in vitro inhibition of insulin secretion by diphenylhydantoin. J Clin Invest. 1970;49(10):1942–1948
  32. Basabe JC, Lopez NL, Viktora JK, et al. Insulin secretion studies in the perfused rat pancreas, I, Effect of tolbutamide, leucine and arginine; their interaction with diazoxide, and relation to glucose. Diabetes. 1971;20:449–456
  33. Fariss BL, Lutcher CL. Diphenylhydantoin-induced hyperglycemia and impaired insulin release. Eff Dosage Diabetes. 1971;20:177–181
  34. Svartberg J, Stridsberg M, Wilander E, et al. Tumor-induced hypoglycemia in a patient with insulin-dependent diabetes mellitus. J Int Med. 1996;239:181–185
  35. Sakurai A, Aizawa T, Katakura M, et al. Insulinoma in a patient with non-insulin-dependent diabetes mellitus. Endocr J. 1997;44(4):473–477
  36. Wildbrett J, Nagel M, Theissig F, et al. An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity. Dtsch Med Wochenschr. 1999;124:248–252
  37. Eriguchi E, Aoyagi S, Hara M, et al. Insulinoma occurring in association with fatty replacement of unknown etiology in the pancreas: report of a case. Surg Today. 2000;30(10):937–941
  38. Ravnik-Oblak M, Janez A, Kocijanicic A. Insulinoma induced hypoglycemia in a type 2 diabetic patient. Wien Klin Wochenschr. 2001;113(9):339–341
  39. Sapountzi P, Charnogursky G, Emanuele MA, et al. Diagnosis of insulinoma using continuous glucose monitoring system in a patient with diabetes. Clin Diabetes. 2005;23(3):140–143
  40. Hameed MF, Hoyle GE, Muir Z. A mysterious case of normalizing blood sugar: insulinoma in a long-standing diabetic patient. Age Aging. 2006;35(3):317–318

PII: S1877-5934(09)00009-5

doi: 10.1016/j.ijdm.2009.03.005

International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 35-37 , April 2009

Article Tools